Veradermics (MANE) Enterprise Value (2024 - 2026)

Veradermics has reported Enterprise Value for 3 years, with the latest figure at -$390.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value changed N/A year-over-year to -$390.8 million; the trailing twelve-month figure through Mar 2026 stood at -$390.8 million (changed N/A YoY), and the FY2025 full-year result was -$141.9 million, down 167.24% from the prior year.
• Enterprise Value for Q1 2026 stood at -$390.8 million, down from -$141.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$53.1 million in Q4 2024, with the low at -$390.8 million in Q1 2026.
• Historically, Enterprise Value has averaged -$195.2 million across 3 years, with a median of -$141.9 million in 2025.
• The largest YoY upside for Enterprise Value was 167.24% in 2025 against a maximum downside of 167.24% in 2025.
• Veradermics' Enterprise Value stood at -$53.1 million in 2024, then tumbled by 167.24% to -$141.9 million in 2025, then slumped by 175.48% to -$390.8 million in 2026.
• The last three Enterprise Value figures came in at -$390.8 million (Q1 2026), -$141.9 million (Q4 2025), and -$53.1 million (Q4 2024), per Business Quant data.